RT @DaveGennert: Leveraging #liquidbiopsy & NGS of bone marrow samples to predict outcomes in pediatric #CARTcell B-ALL patients, Michael P…
Leveraging #liquidbiopsy & NGS of bone marrow samples to predict outcomes in pediatric #CARTcell B-ALL patients, Michael Pulsipher et al find any-level MRD>0 at D28 & early B cell recovery highly predictive of relapse, in @BCD_AACR . https://t.c
RT @BCD_AACR: #InThisIssue: Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Childre…
RT @BCD_AACR: #InThisIssue: Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Childre…
Great paper demonstrating that detectable disease by NGS MRD is highly predictive of ALL relapse post-CAR-T with and without ongoing B-cell aplasia. Loss of B-cell aplasia is an independent risk factor for relapse when occurring early (28 days s/p CAR-T).
RT @BCD_AACR: #InThisIssue: Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Childre…
RT @BCD_AACR: #InThisIssue: Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Childre…
#InThisIssue: Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Children and Young Adults With Acute Lymphoblastic Leukemia. https://t.co/2W7LsuD4cm by Michael A. Pulsipher, MD, @ChildrensLA, @GruppStev
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia https://t.co/6ajKMyXq8p
RT @CARTTherapy: #NGS of #MRD Minimal Residual Disease for Predicting Relapse after Tisa-cel in Children and Young Adults with ALL https://…
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia https://t.co/5ogHhEEiSf
RT @CARTTherapy: #NGS of #MRD Minimal Residual Disease for Predicting Relapse after Tisa-cel in Children and Young Adults with ALL https://…
New 3i Investigator Article Alert!! Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia https://t.co/NusnpU5yrx #sciencetwitter #academictwitte
RT @CARTTherapy: #NGS of #MRD Minimal Residual Disease for Predicting Relapse after Tisa-cel in Children and Young Adults with ALL https://…
RT @CARTTherapy: #NGS of #MRD Minimal Residual Disease for Predicting Relapse after Tisa-cel in Children and Young Adults with ALL https://…
#NGS of #MRD Minimal Residual Disease for Predicting Relapse after Tisa-cel in Children and Young Adults with ALL https://t.co/cmksSanT89 #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @GruppS
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia https://t.co/YxfDKwhEeD
RT @aftimosp: Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Ad…
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia https://t.co/7d9ghEuP9o
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
Sequencing-Based MRD Detection in Bone Marrow May Predict ALL Relapse After CAR T-Cell Therapy https://t.co/CWxm3dAQZo
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
🗝️KEY POINTS ▪️Toxicity of GVD+PD-1 regimen was comparable to GVD regimen, except manageably higher rates of hypothyroidism + autoimmune pneumonitis ▪️PD-1 inhibitor + GVD regimen could be effective 2nd line therapy for #cHL pts 👉 https://t.co/fM36gV4Uu
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
RT @BCD_AACR: #OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9…
#OnlineFirst: Minimal Residual Disease by NGS Predicts Relapse After #Tisagenlecleucel in Pediatric ALL. https://t.co/6Lf3zy9Hpv @GruppSteve @PennMedicine @huntsmancancer @isliquidbiopsy #CARTcell